In recent years, porcine circovirus type 2 (PCV2)-associated postweaning multisystemic wasting syndrome (PMWS) has been reported worldwide. However, to date, PMWS has not been reported in Sweden despite the demonstration of serum antibodies to a PCV2-like virus in Swedish pigs. This communication reports the experimental reproduction of clinical PMWS after inoculation of colostrum-deprived (CD) pigs, derived from a Northern Ireland herd, with an isolate of PCV2 virus recovered from a clinically normal Swedish pig that was necropsied in 1993. The clinical disease and histological lesions observed in CD pigs inoculated with this virus were indistinguishable from those observed in previous studies on CD pigs inoculated with a PCV2 virus isolate recovered from pigs with PMWS. These results highlight the disease potential of PCV2 isolated from regions apparently free of PMWS and suggest that the status of the host and its environment is an important factor in the development of clinical PMWS.
Postweaning multisystemic wasting syndrome (PMWS) is now established as a major disease in pigs in many countries throughout the world. Experimental infections and field studies have indicated that porcine circovirus type 2 (PCV2) is the causal agent of PMWS, 3, 4, 9 although other cofactors, primarily associated with stimulation of the pig immune system, have been shown to be important in the development of the disease. 8 In retrospective studies, serum antibodies to PCV2 in pigs have been demonstrated as early as 1968, 14, 17 and examination of archived pig tissues has revealed cases of PCV2-associated PMWS as early as 1986. 15 Clearly, PMWS is not a new disease of the late 1990s, and a PCV2 virus has been present in the pig population for a considerable period of time.
Although PCV2 antibody has been demonstrated in pigs with and without PMWS in affected areas, more surprisingly, antibodies to PCV2 have also been demonstrated in pigs from apparently PMWS-free countries. This has led to speculation that an antigenically similar, but mutated, ''new'' highly virulent PCV2 vi-rus may have recently emerged in PMWS-affected farms and countries.
To date, PMWS has not been reported in pigs in Sweden, although antibodies to a PCV2 virus are present in the vast majority of Swedish pigs tested. 18 If the hypothesis of a new mutated PCV2 having recently emerged as the causal agent of PMWS is correct, then clearly this new virus is not yet present in Swedish pigs. This communication reports the results of an experimental infection using a PCV2 isolate from a Swedish pig that was necropsied in 1993, well before the emergence of epidemic PMWS in North America or Europe, and negates the hypothesis that the emergence of PMWS is due to the introduction of a new pathogenic strain of PCV2.
Materials and methods
Virus. A Swedish PCV2 virus (S-PCV2) was isolated after inoculation of PCV-free PK/15 cell cultures with a clarified homogenate of lymph node tissues from a pig killed in 1993. This animal originated from a specific pathogen-free (SPF) herd in Sweden established in June 1988 by hand rearing of colostrum-deprived (CD) Swedish Yorkshire piglets derived by cesarean section. This herd was initially seronegative for PCV2 and remained so until the spring of 1993. Seroconversion within the herd to PCV2 coincided with an outbreak of exudative epidermitis (EE). 18 Eight months after the EE outbreak, a clinically normal pig from this farm was sacrificed, and tissues were taken for histological, polmerase chain reaction (PCR), and virological studies. Samples for virus isolation and production of a working pool of PCV2 were processed in PCV-free PK/15 cell cultures with glucosamine as previously described. 16 The working pool of PCV2 used for inoculation of piglets was prepared as a cell culture lysate, after 5 passages in PCV-free PK/15 cell cultures, by three cycles of freezing-thawing. This virus pool was assayed for, and shown not to contain, other contaminating infectious agents, including PCV1 and porcine parvovirus (PPV). An isolate of PPV was also used for experimental disease reproduction experiments. 3 This virus was a field isolate of PPV recovered from tissues from pigs with clinical PMWS. 3, 9 A working pool of this PPV isolate was prepared in PPV-and PCV2-free primary pig kidney cell cultures for inoculation of piglets. This inoculum was demonstrated to be free of PCV1 and PCV2 contamination by PCR. 12 Experimental infection. Experimental infections were carried out on snatch-farrowed, CD (SFCD) piglets obtained from an SPF, PCV2-seropositive herd in Northern Ireland. All pigs in this herd were crossed Large White/Landrace, and, to date, no PCV2-associated disease problems have been reported in this herd. Routine laboratory analysis of tissue samples from pigs from this herd over a 5-yr period have failed to detect histological lesions consistent with PCV2-associated diseases. In addition, examination of tissue samples from over 100 pigs used as controls in previous studies have also failed to detect evidence of PCV2-associated diseases. For experimental infections, piglets were held in a clean but not sterile environment. 3 Four groups of 4-day-old SFCD pigs were used in this experiment. Pigs in group A (n ϭ 4) were infected with 10 5.5 50% tissue culture infective dose (TCID 50 ) of the S-PCV2 virus alone, pigs in group B (n ϭ 9) with 10 5.5 TCID 50 of the S-PCV2 virus and 10 7.0 TCID 50 of the PPV recovered from PMWS-affected pigs, and pigs in group C (n ϭ 4) with 10 7.0 TCID 50 of PPV alone. Pigs in group D (n ϭ 4) were mock infected with PCV/PPV-free cell culture lysate. Pigs were inoculated with 1 ml per nare of the appropriate mixture, and the 4 groups were housed separately. The experiment was terminated at 29 days postinfection (PI). Tissue samples (Table 1) were taken from all pigs, and acetone-fixed cryostat tissue sections were assayed by indirect immunofluorescence for PCV2 antigen, using a PCV2-specific monoclonal antibody 11 or double immunolabeling for PCV2 and PPV antigens. Double immunolabeling was carried out using a rabbit polyclonal antibody to PCV2 and a monoclonal antibody to PPV. Briefly, both these antibodies were diluted in phosphate-buffered saline (PBS) and applied simultaneously to the tissue section. After a 1hr incubation, the sections were washed in PBS and immunostained for 60 min with a 1:100 dilution of fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse immunoglobulin, mixed with an equal volume of a 1:50 dilution of a Texas red-conjugated antirabbit immunoglubulin diluted in PBS containing 10% PCV2 antibody-free pig serum. The sections were washed again, mounted in vectashield a mountant, and examined under ultraviolet illumination using appropriate filters. Selected tissue samples were also taken for histology into 10% neutral buffered formalin and fixed for 3-6 days before routine processing and embedding in paraffin. Serum samples were taken from all pigs before experimental inoculation and at termination of the experiment and assayed for antibody to PCV2 and PPV as described elsewhere. 3 Genomic analyses of Swedish PCV2 isolate. ORF2 sequence determination was carried out on PCV2 nucleic acid extracted from the original lymph node homogenate derived from the Swedish pig killed in 1993, from nucleic acid extracted from the working pool of this virus grown for experimental inoculation, and from nucleic acid extracted from tissues taken from experimentally infected pigs at necropsy. Briefly, oligonucleotide primers that amplified the ORF2 region of PCV2 DNAs (forward: 5Ј GGTAATACTTACA-GCGCACTTC 3Ј and reverse: 5Ј CCCCATGCCCT-GAATTTCC 3Ј) were designed based on the Canadian reference PCV2 sequence (accession No. AF055392). 13 All primers were synthesized by GIB-CO BRL b at a synthesis scale of 50 nmol and desalted. Positive control DNA extracts were prepared from 100 l of PK/15 cell culture extracts infected with the reference Canadian PCV2. 13 An extract from a PK/15 cell culture shown to be free of PCV2 was used as a negative control. All samples were extracted using a QIAmp tissue kit c in accordance with the manufacturers' instructions. In total, DNA samples were extracted from the control reference virus isolate, the original Swedish lymph node tissue homogenate dating from 1993, the cell culture isolate of PCV2 made from the original Swedish clinical specimen that was used as the experimental inoculum, and clinical samples obtained after disease reproduction experiments. After extraction, 2 l of each of the DNA extracts were used as the target in subsequent PCR amplifications. Polymerase chain reaction was carried out using Taq PCR mastermixes c scaled down to final reaction volumes of 25 l. The final concentration of reagents was as follows: 1.5 mM MgCl 2 , 200 M of each deoxynucleoside triphosphate, 0.2 M of each primer, and 0.625 U Taq DNA polymerase. After denaturation at 94 C for 1 min, the reaction mixtures were subjected to thermal cycling in a GeneAmp PCR System 2400 c for 40 ramp cycles each of 94 C for 30 sec, 50 C for 30 sec, and 72 C for 60 sec. A time delay of 72 C for 10 min was included before a 4 C soak. Polymerase chain reaction products were gel purified using a QIAEX II gel extraction kit c after agarose gel electrophoresis in accordance with the manufacturers' instructions, and the nucleotide sequences of query PCR products were determined by dideoxy chemistry. Reactions were carried out using a Big Dye terminator ready reaction cycle sequencing kit d on an Applied Biosystems ABI 3100 automated DNA sequencer d in accordance with the manufacturers' instructions. Sequencing reactions were carried out using the individual amplification primers. The nucleotide sequence of each sample was determined in each direction in duplicate. Nucleic acid sequence data were assembled and edited using ABI Prism Sequence Navigator software. d The resultant nucleotide sequences were further analyzed using the MacDNASIS sequence software. e
Results
Experimental infection. One of the 4 inoculates in group A, which were given S-PCV2 alone, was found dead at 21 days PI and at necropsy had gross lesions consistent with PMWS. 1 These gross lesions included enlarged submandibular, bronchial, mesenteric, iliac, and prefemoral lymph nodes; enlarged and mottled kidneys; and consolidated areas in lung lobes. Histological examination of tissues from this pig revealed microscopic lesions typical of PMWS, including marked expansion of cortical and paracortical zones in affected lymph nodes with infiltration by cells with monocyte/macrophage morphology. There was a marked depletion of lymphocytes in the cortex and paracortex. These lesions were associated with an abundance of PCV2 antigen, as demonstrated after immunostaining of cryostat sections with a PCV2-specific antibody ( Table 1 ). The remaining 3 inoculates in this group were clinically normal when sacrificed at 29 days PI. All 3 of these inoculates had mild to mod-erate gross lesions consistent with PMWS and PCV2 antigen, which is associated with lesions ( Fig. 1) . Five of the 9 pigs inoculated with S-PCV2 and PPV (group B) showed severe clinical signs consistent with PMWS, characterized by wasting and respiratory distress, and were sacrificed at 21-23 days PI. The remaining four inoculates in this group were sacrificed between 26 and 29 days PI. All 9 inoculates in this group had moderate to severe gross and histological lesions consistent with PMWS, as described above, and an abundance of PCV2 antigen, associated with lesions, as demonstrated by immunostaining of cryostat sections (Table 2 ) of the liver (Fig. 2) , spleen ( Fig.  3) , small intestine (SI3) (Fig. 4) , and lung ( Fig. 5 ). Minimal amounts of PPV antigen as demonstrated by dual immunostaining for PCV2 and PPV antigens were detected in tissues from these pigs ( Fig. 6 ).
All piglets in groups C and D, given PPV alone or PCV-free cell culture lysate, were clinically normal for the duration of the experiment, and no gross lesions were seen at necropsy. No PCV2 antigen was demonstrated in tissue samples from these 2 groups of pigs. All preimmune samples taken from the piglets were negative for antibody to PCV2 and PPV. No PPV antibody was detected in the terminal samples from pigs infected with PCV2 alone, and no PCV2 antibody was detected in the terminal serum samples from pigs infected with PPV alone. Antibodies to PPV were detected in terminal samples of all pigs (Table 3) infected with S-PCV2 and PPV (group B) or with PPV alone (group C). Antibodies to PCV2 were also detected in the terminal serum samples from 4 of the 9 pigs infected with S-PCV2 and PPV and from 3 of the 4 pigs infected with S-PCV2 alone ( Table 3) . No PCV2 antibodies were detected in the remaining pigs in these 2 groups.
Genomic analysis. The nucleotide sequence of the ORF2 region of the PCV2 genome amplified from the original Swedish lymph node homogenate exhibited 95.5% nucleotide sequence identity and 96.2% protein sequence identity with the reference Canadian PCV2 isolate (Fig. 7a, 7b ). The ORF2 region of the S-PCV2 isolate was 1 amino acid longer than that observed in the reference Canadian isolate and also contained a number of unique genotypic nucleotide sequence differences. These nucleotide sequence differences facilitated the differentiation of the S-PCV2 isolate from commonly occurring PCV2 isolates. In addition, the cell culture isolate of the S-PCV2 used as the experimental inoculum and the tissue samples obtained after experimental reproduction of S-PCV2-induced disease were also subject to ORF2 sequence analyses. No evidence of either environmental or laboratory contamination was observed in the S-PCV2-infected pigs, and concomitantly it can be concluded that the results * The quantity of PCV2 antigens detected in cryostat sections was scored as ϩ ϭ minimal amount of PCV2 antigen detected in tissue section, increasing to a ϩϩϩϩ ϭ abundant PCV2 antigen detected in tissue section. ND ϭ not determined. * Results are expressed as the reciprocal of the last dilution that gave positive immunostaining in the indirect immunoperoxidase monolayer assay (IPMA) for PCV2 and the indirect fluorescent antibody test (IFAT) for PPV. of disease reproduction experiments were solely due to the pathogenicity of the S-PCV2 isolate.
Discussion
Recent studies on the epidemiology of PMWS in England and elsewhere have suggested that the spread of this disease is typical of a new virus infection in a naive population. 6 However, the majority of pigs on PMWS-negative farms have detectable serum antibody levels to a PCV2 virus, indicating previous subclinical infections. It has been speculated that a new, highly virulent PCV2 is spreading through pig herds in England and elsewhere, causing PMWS, or, alternatively, a new infectious agent, unrelated to PCV2, has emerged and is causing PMWS. The results presented in this article suggest that this is not the case. These results demonstrate that a PCV2 virus isolated from a subclinically infected pig necropsied in 1993 from a herd with no history of PMWS originating from a country reported to be free of PMWS can cause clinical disease and gross lesions consistent with PMWS in an SFCD pig disease model. Importantly, these clinical signs and lesions reproduced using the Swedish isolate of PCV2 were indistinguishable from those ob-tained after similar experimental infections in this model with PCV2 isolates from pigs with PMWS. 3 The possibility that the clinical disease observed after experimental infections with the S-PCV2 isolate was due to contamination of the virus working pool or experimental environment was eliminated by nucleic acid genotyping of PCR-amplified DNAs using target DNAs extracted from the original lymph node material, the virus working pool, and tissues of diseased inoculates. The use of a CD model for experimental studies on the pathogenesis of PCV2 virus has been previously documented. 3, 4 This model negates the substantial problems encountered in locating PCV2 antibody-free piglets, and the use of CD pigs held in a clean but not sterile environment, as opposed to gnotobiotic animals held in a germ-free environment, 8, 9 resembles ''field conditions'' more closely. However, both these models have obvious inherent advantages and disadvantages. Although CD pigs maintained in a clean but not sterile environment may resemble pigs maintained under field conditions more closely, the use of gnotobiotic pigs for experimental studies provides a perfect model for the study of interactions of single infectious agents with the host. 8, 9 In previously report- ed experimental studies, 3, 8, 9 coinfections with other porcine viruses or immunostimulation have been shown to be effective ''triggers'' for enhancing PCV2 replication, resulting in earlier and more severe clinical disease. In addition, field studies have since indicated that immunostimulation, environment, husbandry, and genetic factors may be important in the progression of clinical PMWS. 10 The results of the present study confirm that PCV2 is the causal agent of PMWS and suggest that the PCV2 virus now causing epidemic PMWS has been present in the pig population since at least 1993 without causing any previously recognized clinical disease. Indeed, to date, no PMWS has been recorded in the pig herd from which the S-PCV2 used in this study was isolated. The reasons why no PCV2-associated clinical diseases have been seen in Sweden are not known but may relate to changes in the global pig industry that have not been applied in this country. From an international perspective the mean herd size in Sweden is not large, and the breeding programs have been dominated by domestic animals. 5 From 1995, imports have included only animals from Finland and Norway, countries with a similar pig health status to Sweden.
Alternatively, the freedom of Swedish pigs from PMWS, but not PCV2 infection, could be related to the absence of other infectious agents from the national Swedish pig population that are common in countries with PMWS, which could act as triggers for PCV2 replication and subsequent disease. Presently, pigs in Sweden are declared free from all infections present on the A-list of the International Office of Epizootics (OIE) as well as from porcine endemic diarrhea, porcine reproductive and respiratory syndrome, and transmissible gastroenteritis. Aujeszky disease was eradicated in 1997, and Salmonella has been diagnosed in less than 5 pig herds per year since 1984. All breeding and multiplying herds are declared free from dysentery, atrophic rhinitis, and mange. With respect to PPV, sows and gilts are generally vaccinated before each service, and disease outbreaks are rare despite the agent being endemic. A ban on growth promoters (i.e., administration of low-dose antibiotics to feed) effected in 1986 has contributed to an improved standard of management and hygiene systems in Swedish pig farms. As a result, the performance of the pigs has increased, and the incidence of pathological lesions recorded at slaughter has decreased. 7 Presently, around 80% of Swedish pigs are reared in age-segregated systems from birth to weaning.
As expected, serological studies performed on terminal serum samples collected at necropsy demonstrated antibodies to PPV in serum from all pigs in appropriately infected groups. However, detection of PCV2 antibodies in terminal serum from pigs in groups infected with S-PCV2 was much lower than expected. One of the pigs in the S-PCV2-only infected group had no detectable antibody when necropsied at 21 days after infection. The remaining 3 pigs in this group all had low to medium levels of PCV2 antibody in serum samples collected 29 days after infection. In the group infected with S-PCV2 and PPV, 5 pigs that were necropsied between 21 and 26 days after infection had no detectable PCV2 antibody. The 4 pigs that had demonstrable PCV2 antibodies in serum were necropsied between 21 and 29 days after infection. It is probable (supported by unpublished data) that these results indicate that in this experimental model seroconversion to PCV2 is relatively slow, occurring at its earliest around the third week after infection and as late as 4 weeks after infection. It is of note that all the pigs necropsied 29 days after infection had seroconverted to PVC2.
In conclusion, the results of this study confirm that clinical PMWS can be experimentally reproduced by inoculation of SFCD piglets with a PCV2 virus isolated from a PMWS-free country and that in this experimental model the disease process is accelerated by, but is not dependent on, coinoculation of piglets with PPV. More importantly, however, it has been demonstrated here for the first time that PMWS can be reproduced in an SFCD pig model by experimental inoculation of a PCV2 isolate from a pig necropsied in 1993 that had no clinical disease or histological lesions of PMWS. These findings strongly suggest that the status of the host and the environment are critical factors in the development of PMWS after infection with PCV2.
